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OBJECTIVE: To assess “real world” drug persistence
patterns for patients with Alzheimer’s Disease (AD)
treated with clinically effective doses of rivastigmine or
donepezil by evaluating rates of discontinuation and
change in therapy. METHODS: A retrospective cohort
study was conducted using longitudinal pharmacy claims
data from the PharMetrics Patient-Centric database.
Newly treated, US, community-based AD patients were
identiﬁed as having an initial prescription (index event)
for rivastigmine or donepezil between June and Decem-
ber, 2000. Patients receiving either drug during the 180
days prior to their index prescription or who did not have
continuous plan enrollment during this period were
excluded. Patients reaching clinically effective doses 
of donepezil (5..C10mg/day) or rivastigmine (6..C12
mg/day), and undergoing ≥ 60 days continuous therapy
were analyzed. The primary outcome measure was time
to treatment failure, deﬁned as either discontinuation of
therapy (no prescription reﬁll within 90 days of estimated
completion of prior prescription) or switch to alternative
AD drug. Kaplan-Meier survival and proportional hazard
model analyses were performed. RESULTS: A total of
1650 AD patients treated with rivastigmine or donepezil
met all study eligibility criteria and reached clinically
effective doses. Treatment failure occurred for 66% of
donepezil patients (27% within ﬁrst 60 days) and 60%
of rivastigmine patients (20% within ﬁrst 60 days) during
the approximate 1-year follow-up. The mean (95% CI)
time to failure was 360 (332..C398) days for the rivastig-
mine group versus 376 (361..C391) days for donepezil 
(p = 0.083). In patients receiving the maximum recom-
mended doses, mean time to treatment failure was 392
(372..C412) days with donepezil 10mg/day versus 403
(352..C454) days for rivastigmine 12mg/day (p = 0.24).
CONCLUSIONS: Drug persistence patterns were similar
for rivastigmine and donepezil patients who reach a clin-
ically effective dose, but there was a trend in favor of
rivastigmine for patients reaching higher doses.
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STANDARD GAMBLE TECHNIQUE—A TOOL TO
ASSESS QUALITY OF LIFE IN PATIENTS WITH
EPILEPSY
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1University of Shefﬁeld, Shefﬁeld, United Kingdom;
2GlaxoSmithKline, Uxbridge, United Kingdom
OBJECTIVE: Epilepsy treatment and associated side-
effects have signiﬁcant impact on patients’ health-related
quality of life (HRQoL). Literature suggests that generic
tools (eg EQ-5D) are not appropriate in epilepsy. This
analysis assesses impact on HRQoL of three common
anti-epileptic drugs using standard gamble (SG) tech-
nique. METHOD: A questionnaire was administered to
65 members of the public without epilepsy (age 18–86)
deriving scores for seven health states. Health states cor-
responded to epilepsy treatment side-effect proﬁles and
associated occurrence probabilities with monotherapy:
sodium valproate/VPA [weight gain (30%), hair loss
(10%), body hair growth], lamotrigine/LTG [rash (10%)]
and carbamazepine/CBZ [lack of concentration (10%),
perceived impaired intelligence by others]. Questionnaire
for women of childbearing potential/WCBP (aged 18–45)
included failure of oral contraception and possibilities 
of foetal abnormalities (CBZ). Utility scores were derived
using standard methodology. RESULTS: Sixty-four
respondents completed the exercise: 46 female (17
WCBP), 18 male; average age 51.7 years. None had
epilepsy; 10 had a family member with epilepsy. Respon-
dents’ utility values [mean (SD)]: 1. Patients controlled:
LTG 0.751 (0.300), VPA 0.748 (0.307), CBZ 0.712
(0.338); 2. Patients partially controlled: LTG 0.743
(0.308), VPA 0.706 (0.322), CBZ 0.689 (0.340). Uncon-
trolled epilepsy (no treatment) was valued at 0.571 (SD
0.380). Utility values for WCBP with partial control were
higher for LTG (0.837; SD 0.236) versus CBZ (0.658; SD
0.359) and VPA (0.702; SD 0.314). Utilities for treat-
ments yielding full control were higher than those with
partial control. Results are in line with published data 
on epilepsy. Testing showed no signiﬁcant differences
between respondent sub-groups on any domain. CON-
CLUSION: Results indicate that both seizure control and
treatment side-effects affect utility. SG is a valuable
methodology for deriving utilities in epilepsy (compared
to generic instruments) for cost-effectiveness analyses
(CEA). Applying ﬁndings to a decision-tree CEA yielded
£13,045/QALY (range £8,928–£18,960) for lamotrigine
over sodium valproate and carbamazepine.
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LINGUISTIC VALIDITY OF 5 NEW LANGUAGES:
PORTUGUESE, JAPANESE, HEBREW, RUSSIAN,
AND KOREAN
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OBJECTIVE: To evaluate the performance of newly-
translated Portuguese, Japanese, Hebrew, Russian, and
Korean FAMS questionnaires. METHODS: Using both
qualitative and quantitative data, we assessed the prelim-
inary psychometric properties of the translations. The
